Loading patent…
AssigneesMerck & Co., Inc., Whitehead Insitute of Biomedical Research, MedImmune, LLC, Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.
InventorsJohn W. Shiver, Michael D. Miller, Romas Geleziunas, Daria J. Hazuda, Peter S. Kim, Debra M. Eckert, Michael J. Root, Simon N. Lennard, Elisabetta Bianchi
Estimating the term…
Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as VH and VL chains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.
An isolated HIV monoclonal antibody comprising an antibody binding portion that interacts with a conformational epitope within a groove of adjacent coils of a trimeric pre-hairpin intermediate structure of the heptad repeat 1 (HR1) region of the ectodomain of gp41, wherein said conformational epitope comprises amino acids Leu568, Trp571 and Lys574 that occupy one or the other of the adjacent coils within the trimeric pre-hairpin structure and wherein said antibody inhibits HIV infection of a target cell in vitro, wherein said antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein said VH region and said VL region each comprise three complementarity determining regions (CDR) and four framework (FW) regions arranged from the NH2 terminus to the COOH terminus as follows:
An isolated HIV monoclonal antibody comprising an antibody binding portion that interacts with a conformational epitope within a groove of adjacent coils of a trimeric pre-hairpin intermediate structure of the heptad repeat 1 (HR1) region of the ectodomain of gp41, wherein said conformational epitope comprises amino acids Leu568, Trp571 and Lys574 that occupy one or the other of the adjacent coils within the trimeric pre-hairpin structure and wherein said antibody inhibits HIV infection of a target cell in vitro, wherein said antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein said VH region and said VL region each comprise three complementarity determining regions (CDR) and four framework (FW) regions arranged from the NH2 terminus to the COOH terminus as follows:
An isolated HIV monoclonal antibody comprising an antibody binding portion that interacts with a conformational epitope within a groove of adjacent coils of a trimeric pre-hairpin intermediate structure of the heptad repeat 1 (HR1) region of the ectodomain of gp41, wherein said conformational epitope comprises amino acids Leu568, Trp571 and Lys574 that occupy one or the other of the adjacent coils within the trimeric pre-hairpin structure and wherein said antibody inhibits HIV infection of a target cell in vitro, wherein said antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the heavy chain variable (VH) region comprises SEQ ID NO:4 or SEQ ID NO:10.
Dependencies are inferred from the claim text.